Apellis Pharmaceuticals announced that the FDA has granted Fast Track designation to the Company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA), an advanced form of age-related macular degeneration. The FDA’s Fast Track program facilitates the development and expedites the review of drugs to treat serious conditions and fill an unmet medical need, allowing important new drugs to reach the pati...